Stem Cell Therapeutics Corp. Congratulates Dr. Samuel Weiss on His Receipt of the Gairdner Award
April 16 2008 - 1:53PM
Marketwired
CALGARY, ALBERTA (TSX VENTURE: SSS) is proud to congratulate Dr.
Samuel Weiss, Director of the Hotchkiss Brain Institute at the
University of Calgary, for receiving the distinguished Gairdner
Award. This esteemed award was granted to Dr. Weiss "for his
seminal discovery of adult neural stem cells in the mammalian brain
and its importance in nerve cell regeneration".
Dr. Weiss discovered that the adult brain can produce new cells
- adult stem cells - that can grow into new brain cells called
neurons. The finding raised the prospect of regenerating damaged
nerves with stem cells the brain can produce itself. Dr Weiss' stem
cell regenerative work is the foundation of SCT's therapeutic
approach to stroke, traumatic brain injury and multiple sclerosis.
He continues his association with SCT as a key member of its
Scientific Advisory Board.
Dr. Alan Moore, President of Stem Cell Therapeutics Corp.
commented as follows:
"We are delighted to see Dr. Weiss win this prestigious award.
Stem Cell Therapeutics is making good progress in our efforts to
commercialize Dr Weiss's scientific discovery which has the
potential to provide significant benefits for indications such as
stroke, multiple sclerosis and traumatic brain injury where there
are currently limited options available for treatment"
About the Gairdner Award (http://www.gairdner.org/): The core
mandate of the Gairdner Foundation is to select the annual Gairdner
International Award winners. Over the past 48 years, the Foundation
has gained a superb international reputation through its
international awards, for recognizing and rewarding early the work
of the world's leading scientists. An external measure of their
stature is the fact that of the 288 individuals from 13 countries,
including 42 Canadians, who have received Gairdner Awards, 70 have
subsequently gone on to win the Nobel Prize.
About NTx(TM)-265: NTx(TM)-265 is a therapeutic regimen of two
approved and clinically well-defined drugs, human Chorionic
Gonadotropin (hCG) and Erythropoietin (EPO), targeting the
treatment of stroke. The twin objectives of the regimen are to
stimulate the growth and differentiation of new neurons to replace
the brain cells that were lost or damaged by the stroke, and
importantly, to direct motor, visual and cognitive recovery after
acute ischemic stroke. Animal studies have shown a significant
recovery in motor function after receiving the NTx(TM)-265 regimen
24-48 hours post stroke. Encouraging clinical results in SCT's
Phase IIa BETAS stroke trial were presented at the International
Stroke Conference in February 2008. SCT is enrolling sites for the
multi-centre, double-blind, placebo-controlled Phase IIb REGENESIS
study for NTx(TM)-265 with primary endpoints of efficacy; enrolment
to be complete by the end of 2008 with top-line efficacy data to be
released before the end of the first quarter of 2009.
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp.
is a Canadian public biotechnology company (TSX VENTURE: SSS)
focused on the development and commercialization of drug-based
therapies to treat central nervous system diseases. SCT is a leader
in the development of therapies that utilize drugs to stimulate a
patient's own resident stem cells. The company's programs aim to
repair neurological function lost due to disease or injury. The
company's extensive patent portfolio of owned and licensed
intellectual property supports the potential expansion into future
clinical programs in numerous neurological diseases such as
traumatic brain injury and multiple sclerosis.
These securities have not been registered under the United
States Securities Act of 1933, as amended, or the securities laws
of any state, and may not be offered or sold within the United
States or to, or for the account or benefit of U.S. persons unless
an applicable exemption from U.S. registration requirements is
available.
Except for historical information, this press release may
contain forward-looking statements, which reflect the Company's
current expectation regarding future events. These forward-looking
statements involve risk and uncertainties, which may cause but are
not limited to, changing market conditions, the successful and
timely completion of clinical studies, the establishment of
corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to
time in the Company's ongoing quarterly and annual reporting.
The TSX Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release.
Contacts: Stem Cell Therapeutics Corp. Alan Moore, PhD President
and CEO (403) 245-5495 ext.224 Email: amoore@stemcellthera.com Stem
Cell Therapeutics Corp. Chloe Douglas-Crampton Corporate Secretary
(403) 245-5495 ext. 221 Email: crampton@stemcellthera.com Website:
www.stemcellthera.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024